HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Registrational
- Acronyms HOMERUS
- Sponsors Roche
- 02 May 2017 Planned End Date changed from 1 Jul 2018 to 6 Jul 2018.
- 02 May 2017 Planned primary completion date changed from 1 Jul 2018 to 6 Jul 2018.
- 11 Oct 2016 Interim safety results of this and other four phase 3 studies presented at the 41st European Society for Medical Oncology Congress (2016).